Literature DB >> 29322612

Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations.

Li Song1, Changdong Guan1, Hongbing Yan1, Shubin Qiao1, Yongjian Wu1, Jinqing Yuan1, Kefei Dou1, Yuejin Yang1, George D Dangas2, Bo Xu1.   

Abstract

OBJECTIVES: We aimed to assess the prognostic ability of the ST score, DAPT score, and PARIS score in a Chinese population.
BACKGROUND: Recently, several risk scores predicting the long-term risk of coronary thrombotic events [CTE, defined as the composite of definite or probable stent thrombosis (ST) and myocardial infarction] and bleeding have been developed and initially validated in Western populations.
METHODS: A total of 6,088 consecutive patients with acute coronary syndrome (mean age 58.3 ± 10.4; women 23.1%) treated with drug-eluting stents in 2013 at our single institution were enrolled. We calculated risk scores and evaluated their performance for predicting definite or probable ST, CTE and major bleeding (MB, defined as the occurrence of a Bleeding Academic Research Consortium type 3 or 5 bleed). The prognostic value of risk scores was assessed by receiver-operating characteristic curves.
RESULTS: The ST score, DAPT score, and PARIS score all showed unsatisfactory discrimination to predict 2-year or 1- to 2-year ST and CTE (c-statistic = 0.51-0.59). With respect to bleeding outcomes, the PARIS score showed unsatisfactory discrimination in predicting 2-year MB (c-statistic = 0.56); the DAPT score performed slightly better than the PARIS score in predicting occurrence of later MB events between 1 and 2 years, whereas its discriminative capacity was only modest (c-statistic = 0.71).
CONCLUSIONS: The current three risk scores, derived and initially validated in Western populations, may not be applicable to the Chinese population, although DAPT score was determined to be a modestly accurate quantitative tool for prediction of later MB.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  acute coronary syndrome; dual-antiplatelet therapy; major bleeding; risk score; stent thrombosis

Mesh:

Substances:

Year:  2018        PMID: 29322612     DOI: 10.1002/ccd.27468

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  5 in total

1.  Validity of the Stent Thrombosis Risk Score in Predicting Early Stent Thrombosis after Primary Percutaneous Coronary Intervention.

Authors:  Rajesh Kumar; Sahar Tariq; Madiha Fatima; Tahir Saghir; Mahesh Kumar Batra; Musa Karim; Jawaid Akbar Sial; Naveedullah Khan; Syed Nadeem Hasan Rizvi
Journal:  J Saudi Heart Assoc       Date:  2020-06-01

2.  Validation of Predictive Value of Patterns of Nonadherence to Antiplatelet Regimen in Stented Patients Thrombotic Risk Score in Chinese Population Undergoing Percutaneous Coronary Intervention: A Prospective Observational Study.

Authors:  Xue-Yan Zhao; Jian-Xin Li; Xiao-Fang Tang; Jing-Jing Xu; Ying Song; Lin Jiang; Jue Chen; Lei Song; Li-Jian Gao; Zhan Gao; Shu-Bin Qiao; Yue-Jin Yang; Run-Lin Gao; Bo Xu; Jin-Qing Yuan
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

Review 3.  A Systematic Review on Bleeding Risk Scores' Accuracy after Percutaneous Coronary Interventions in Acute and Elective Settings.

Authors:  Crischentian Brinza; Alexandru Burlacu; Grigore Tinica; Adrian Covic; Liviu Macovei
Journal:  Healthcare (Basel)       Date:  2021-02-02

4.  A Novel Multiple Risk Score Model for Prediction of Long-Term Ischemic Risk in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: Insights From the I-LOVE-IT 2 Trial.

Authors:  Miaohan Qiu; Yi Li; Kun Na; Zizhao Qi; Sicong Ma; He Zhou; Xiaoming Xu; Jing Li; Kai Xu; Xiaozeng Wang; Yaling Han
Journal:  Front Cardiovasc Med       Date:  2022-01-13

5.  Contradictions between DAPT and PRECISE-DAPT scores with the severity of coronary lesion in acute coronary syndrome.

Authors:  Sisi Bi; Yue Zhao; Qingling Peng; Wenxue Liu; Guogang Zhang; Chenglong Zhang
Journal:  Medicine (Baltimore)       Date:  2020-04       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.